Publication details

Stromal cells engineered to express T cell factors induce robust CLL cell proliferation in vitro and in PDX co-transplantations allowing the identification of RAF inhibitors as anti-proliferative drug

Investor logo
Investor logo
Authors

HOFERKOVÁ Eva ŠEDA Václav CESNÁRIKOVÁ Soňa VERNER Jan LOJA Tomáš MATULOVÁ Květoslava SKUHROVÁ FRANCOVÁ Hana ONDROUŠKOVÁ Eva FILIP Daniel BLAVET Nicolas BOUDNÝ Miroslav MLADONICKÁ PAVLASOVÁ Gabriela VEČEŘA Josef ONDRIŠOVÁ Laura PAVELKOVÁ Petra HLAVÁČ Kryštof KOŠŤÁLOVÁ Lenka MICHAELOU Androniki POSPÍŠILOVÁ Šárka DORAZILOVÁ Jana CHOCHOLA Václav JAROŠ Josef DOUBEK Michael JAROŠOVÁ Marie HAMPL Aleš VOJTOVÁ Lucy KŘEN Leoš MAYER Jiří MRÁZ Marek

Year of publication 2024
Type Article in Periodical
Magazine / Source Leukemia
MU Faculty or unit

Central European Institute of Technology

Citation
web https://www.nature.com/articles/s41375-024-02284-w
Doi http://dx.doi.org/10.1038/s41375-024-02284-w
Keywords stromal cells; T cell factors; CLL cell proliferation
Attached files
Description Several in vitro models have been developed to mimic chronic lymphocytic leukemia (CLL) proliferation in immune niches; however, they typically do not induce robust proliferation. We prepared a novel model based on mimicking T-cell signals in vitro and in patient-derived xenografts (PDXs). Six supportive cell lines were prepared by engineering HS5 stromal cells with stable expression of human CD40L, IL4, IL21, and their combinations. Co-culture with HS5 expressing CD40L and IL4 in combination led to mild CLL cell proliferation (median 7% at day 7), while the HS5 expressing CD40L, IL4, and IL21 led to unprecedented proliferation rate (median 44%). The co-cultures mimicked the gene expression fingerprint of lymph node CLL cells (MYC, NF?B, and E2F signatures) and revealed novel vulnerabilities in CLL-T-cell-induced proliferation. Drug testing in co-cultures revealed for the first time that pan-RAF inhibitors fully block CLL proliferation. The co-culture model can be downscaled to five microliter volume for large drug screening purposes or upscaled to CLL PDXs by HS5-CD40L-IL4?±?IL21 co-transplantation. Co-transplanting NSG mice with purified CLL cells and HS5-CD40L-IL4 or HS5-CD40L-IL4-IL21 cells on collagen-based scaffold led to 47% or 82% engraftment efficacy, respectively, with ~20% of PDXs being clonally related to CLL, potentially overcoming the need to co-transplant autologous T-cells in PDXs.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info